Treated patients with advanced non-small cell lung cancer
Conditions
Interventions
nab-paclitaxel(100mg/m2) day1,8,15 q3weeks
Sponsors
Tohoku Medical and Pharmaceutical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically confirmed non-sqamous non-small-cell lung cancer with chemotherapy treated patients 2) Stage III/IV without indication for curative resection and irradiation or post-operative recurrent disease 4) ECOG performance status 0-2 5) Adequate organ function 6) Excepted to live over 3 months after administration day 7) Written informed consent from the patients
Exclusion criteria
Exclusion criteria: 1) Interstitial pneumonia/lung fibrosis on chest CT. 2) Previous drug allergy 3) History of poorly controlled pleural effusion, pericardial effusion and ascites. 4) Active infection. 5) Current Diarrhea. 6) Ileus or intestinal tract paralysis. 7) Symptomatic brain metastasis. 8) Active concomitant malignancy. 9) History of sever heart disease. 10) History of sever psychological disease. 11) Those judged to be not suitable by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RR: response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS: progression free survival OS: overall survival DCR: disease control rate Toxicity | — |
Countries
Japan
Contacts
Public ContactNaruo Naruo
Tohoku Medical and Pharmaceutical University Department of pulmonology
Outcome results
None listed